Navigation Links
AspenBio Pharma Changes Company Name to Venaxis, Inc.
Date:12/12/2012

dicitis, allowing for more conservative patient management.  APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") (formerly AspenBio Pharma, Inc.) as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from APPY1, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize val
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AspenBio Pharma Engages Tiberend Strategic Advisors as Investor and Public Relations Agency of Record
2. AspenBio Pharma Executes Worldwide License Agreement for its Animal Health Assets
3. AspenBio Pharma to Provide Shareholders with Business Update
4. AspenBio Pharma Begins Training Hospital Sites for Pivotal Clinical Trial
5. AspenBio Pharma Announces Proposed Public Offering
6. AspenBio Pharma Announces Pricing of Public Offering of 1,476,000 Shares of Common Stock
7. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
8. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
9. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
10. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will ... the Australian and New Zealand Forensic Science Society,s ... Sciences in Adelaide, Australia . ... concerning the advancements that hyperspectral imaging can bring ... Jeffrey Beckstead , Director of Product Development at ...
(Date:8/29/2014)... Aug. 29, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the CL ... on Tuesday, September 9, 2014 at 12:30 p.m. ET. ... Place Hotel in New York City ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... clinical study to evaluate multiple ascending doses of NKTR-181, ... in development as a once- or twice-daily oral tablet ... to address the abuse liability and serious central nervous ...
... 8, 2011 Reportlinker.com announces that a ... its catalogue: Global Intravenous ... http://www.reportlinker.com/p0611078/Global-Intravenous-IV-Solutions-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_E This report analyzes ... in US$ Million. The report provides separate ...
Cached Medicine Technology:Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 2Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 4Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 5Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 6Global Intravenous (IV) Solutions Industry 2Global Intravenous (IV) Solutions Industry 3Global Intravenous (IV) Solutions Industry 4Global Intravenous (IV) Solutions Industry 5Global Intravenous (IV) Solutions Industry 6Global Intravenous (IV) Solutions Industry 7Global Intravenous (IV) Solutions Industry 8
(Date:8/30/2014)... “In 2013, a vehicle crash occurred every 5 ... a recently released article on 2013 Washington auto accident ... auto accident every 12 minutes, and a motorcyclist is involved ... the 2013 statistics, between now and this same time tomorrow, ... of an auto accident is real and impending - five ...
(Date:8/30/2014)... 30, 2014 Barton Associates, an industry ... locum tenens company , announces a new office location ... Barton Associates is headquartered in Peabody, MA, with additional ... and Jupiter, FL. , Barton Associates decided ... demand for healthcare providers. The United States is in ...
(Date:8/30/2014)... Saturday 30 August 2014: The first multidisciplinary recommendations ... acute coronary syndromes (ACS) are published today in ... was written jointly by the European Heart Rhythm ... and the European Association of Percutaneous Cardiovascular Interventions ... Bulent Gorenek (Turkey), chairperson of the task force, ...
(Date:8/30/2014)... The therapeutic benefit of revascularisation in coronary artery ... revascularisation guidelines presented at ESC Congress by joint ... the European Society of Cardiology (ESC) and Professor ... Cardio-Thoracic Surgery (EACTS). The joint guidelines are published ... (1), on the ESC Website (2), in EuroIntervention ...
(Date:8/29/2014)... 30, 2014 AGH Healthy Happenings, a ... Doctors in Delaware at Atlantic General Hospital, are ... services. In addition to no-cost blood pressure screenings at ... aid care at local sports tournaments. , In ... staff provide free disease management and falls prevention workshops ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 3Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 3
... Strictly embargoed until: 00.01 GMT, Friday, 12 October, ... world,s,maternal mortality ratio (the number of maternal deaths per ... Development Goal (MDG),5, which aims to improve maternal health ... While an annual decline of 5.5 per cent in ...
... Calif., Oct. 11 Each year, more than,90,000 ... of gynecological cancer.,Although the overall death rate for ... cancer has increased slightly. Dr. Stan Wasbin, ... provides an overview of gynecological,cancer, stressing the importance ...
... little,cooler for the patients at Children,s National Medical Center, ... will make their annual,visit. The team will also launch ... Caps., Courage Caps are team-issued and branded hats ... games and online at NHL.com, with,100 percent of the ...
... Cancer researchers have long worked to understand why some ... to stop the production of testosterone and other androgens ... detected that androgen-synthesizing proteins are present within cancer cells, ... to produce their own androgens. , The presence ...
... School of Medicine have found that professional welders who ... at risk for loss of sense of smell. ... the first study to clearly demonstrate that welders who ... at risk for damaging their sense of smell, says ...
... 11 Six earthbound "angels" who have,brightened the lives ... Shield of Michigan. The Caring for Children Angel ... children,s lives. The awards have been,sponsored annually by the ... be honored at a Friday, Nov. 9 reception and ...
Cached Medicine News:Health News:Maternal Mortality Declining in Middle-income Countries; Women Still Die in Pregnancy and Childbirth in Low-income Countries 2Health News:Maternal Mortality Declining in Middle-income Countries; Women Still Die in Pregnancy and Childbirth in Low-income Countries 3Health News:The Silent Killer, Ovarian Cancer on Your Cancer Today (TM) 2Health News:New research may show why some prostate cancer recurs after treatment 2Health News:New research may show why some prostate cancer recurs after treatment 3Health News:Penn study suggests professional welders at risk for loss of sense of smell 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 3
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... Akers, our ultimate goal is to provide ... and immediate treatment. Each year millions of ... die from late detection or undetected disease ... cripple nations., ,By developing, manufacturing and marketing ...
... BD Macro-Vue RPR (Rapid Plasma Reagin) ... Tests are nontreponemal testing procedures for ... in A Manual of Tests for ... manual are the most widely used ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
Medicine Products: